Registration Options

Activity Dates: 04/24/2020 - 04/24/2023

Members can access this product for only $35. Log in or Join now!

Target Audience

This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Attention deficit/hyperactivity disorder (ADHD) is one of the more common psychiatric diagnoses within the pediatric population. While rates may decline with age, a large percentage of these individuals will continue to meet criteria for diagnosis in adulthood.

Within the past five years, a number of new stimulant formulations have entered the market. Given the various formulations, health care providers will benefit from an understanding of the pharmacokinetics and other key parameters, between the newer formulations compared to currently available products. This will allow them to determine the most appropriate product for a given patient.

The role of the pharmacist has expanded and collaborative practice models may now include ADHD management.

Beyond these recently approved agents and expanded pharmacist roles, new guidance has been released regarding the use of 2D6 phenotype to determine initial atomoxetine dose titration. This session will describe how to utilize genetic data and individual patient factors to select the most appropriate ADHD treatment for an individual patient.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course. (sign in first)
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (sign in first)
  • Complete the evaluation at the end of the activity. (sign in first)
  • If necessary, complete the post-test retest no later than the closing activity date. (sign in first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (sign in first)

Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information and Disclosures

Clayton English, PharmD, BCPS, BCPP, BCGP

View biographical information and disclosures

Learning Objectives

  1. Compare and contrast available stimulant formulations for the treatment of attention deficit/hyperactivity disorder (ADHD).
  2. Select an appropriate stimulant formulation for a patient with ADHD using the medications’ unique pharmacokinetic profiles.
  3. Describe the role of pharmacists in optimizing the management of patients with ADHD.
  4. Discuss the role of pharmacogenomics in pharmacotherapy selection in ADHD.

Continuing Education Credit and Disclosures

Activity Dates: 04/24/2020 - 04/24/2023
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-20-033-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.